Skip to content

Study · Randomized controlled trial · n = 464 · 2018

9 results

Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.

Guja C, Frías JP, Somogyi A, Jabbour S, Wang H, Hardy E, Rosenstock J

Diabetes, obesity & metabolism25 Mar 2018Cited by 55 (Europe PMC)

PMID29473704 (opens in a new tab)PMCIDPMC6032936 (opens in a new tab)DOI10.1111/dom.13266 (opens in a new tab)PepBankPUB-29473704
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In uncontrolled T2DM, exenatide added to insulin glargine reduced HbA1c more than placebo added to insulin glargine.

    In plain wordsIn diabetes, adding exenatide to insulin reduced long-term blood sugar more than adding placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c change
    Study

    n = 464

    Comparator
    Placebo plus insulin glargine
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2 mg once weekly · 28 weeksAs given in this study (human).

    Measurements

    HbA1c difference
    −0.73%
    versus placebo plus IG
    Final HbA1c
    7.55%
    exenatide QW plus IG
    Final HbA1c
    8.24%
    placebo plus IG

    Source sentences

    Summary
    Exenatide QW + IG vs placebo + IG significantly reduced HbA1c (least-squares mean difference, -0.73% [-8.0 mmol/mol]; 95% confidence interval, -0.93%, -0.53% [-10.2, -5.8 mmol/mol]; P < .001; final HbA1c, 7.55% [59 mmol/mol] and 8.24% [67 mmol/mol], respectively)
    1 context sentence
    Summary · context
    To compare the efficacy and safety of adding the glucagon-like peptide-1 receptor agonist exenatide once weekly (QW) 2 mg or placebo among patients with type 2 diabetes who were inadequately controlled despite titrated insulin glargine (IG) ± metformin.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In uncontrolled T2DM, exenatide added to insulin glargine reduced body weight versus placebo added to insulin glargine.

    In plain wordsIn diabetes, adding exenatide to insulin reduced weight more than adding placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBody weight
    Study

    n = 464

    Comparator
    Placebo plus insulin glargine
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2 mg once weekly · 28 weeksAs given in this study (human).

    Measurements

    Weight difference
    −1.5 kg
    versus placebo plus IG

    Source sentences

    Summary
    body weight (-1.50 kg; -2.17, -0.84; P < .001)
    1 context sentence
    Summary · context
    To compare the efficacy and safety of adding the glucagon-like peptide-1 receptor agonist exenatide once weekly (QW) 2 mg or placebo among patients with type 2 diabetes who were inadequately controlled despite titrated insulin glargine (IG) ± metformin.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In uncontrolled T2DM, exenatide added to insulin glargine reduced postprandial glucose versus placebo added to insulin glargine.

    In plain wordsIn diabetes, adding exenatide to insulin reduced blood sugar after meals more than adding placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePostprandial glucose
    Study

    n = 464

    Comparator
    Placebo plus insulin glargine
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2 mg once weekly · 28 weeksAs given in this study (human).

    Measurements

    2-hour postprandial glucose difference
    −1.52 mmol/L
    versus placebo plus IG

    Source sentences

    Summary
    and 2-hour postprandial glucose (-1.52 mmol/L [-27.5 mg/dL]; -2.15, -0.90 [-38.7, -16.2]; P < .001).
    1 context sentence
    Summary · context
    To compare the efficacy and safety of adding the glucagon-like peptide-1 receptor agonist exenatide once weekly (QW) 2 mg or placebo among patients with type 2 diabetes who were inadequately controlled despite titrated insulin glargine (IG) ± metformin.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In uncontrolled T2DM, daily insulin glargine dose increased less with exenatide than placebo, by 2 versus 4 units.

    In plain wordsIn diabetes, insulin dose increased less when exenatide was added than when placebo was added.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseDaily insulin glargine dose
    Study

    n = 464

    Comparator
    Placebo plus insulin glargine
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2 mg once weekly · 28 weeksAs given in this study (human).

    Measurements

    Daily IG dose increase
    2 units
    exenatide QW plus IG
    Daily IG dose increase
    4 units
    placebo plus IG

    Source sentences

    Summary
    Significantly more exenatide QW + IG-treated patients vs placebo + IG-treated patients reached HbA1c <7.0% (<53 mmol/mol) (32.5% vs 7.4%; P < .001); daily IG dose increased by 2 and 4 units, respectively.
    1 context sentence
    Summary · context
    To compare the efficacy and safety of adding the glucagon-like peptide-1 receptor agonist exenatide once weekly (QW) 2 mg or placebo among patients with type 2 diabetes who were inadequately controlled despite titrated insulin glargine (IG) ± metformin.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In uncontrolled T2DM, more patients reached HbA1c <7.0% with exenatide plus insulin glargine than placebo plus insulin glargine.

    In plain wordsIn diabetes, more patients reached the blood sugar target when exenatide was added to insulin than when placebo was added.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseHbA1c target attainment
    Study

    n = 464

    Comparator
    Placebo plus insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2 mg once weekly · 28 weeksAs given in this study (human).

    Measurements

    Target attainment
    32.5%
    exenatide plus IG
    Target attainment
    7.4%
    placebo plus IG

    Source sentences

    Summary
    Significantly more exenatide QW + IG-treated patients vs placebo + IG-treated patients reached HbA1c <7.0% (<53 mmol/mol) (32.5% vs 7.4%; P < .001); daily IG dose increased by 2 and 4 units, respectively.
    1 context sentence
    Summary · context
    To compare the efficacy and safety of adding the glucagon-like peptide-1 receptor agonist exenatide once weekly (QW) 2 mg or placebo among patients with type 2 diabetes who were inadequately controlled despite titrated insulin glargine (IG) ± metformin.
  6. 06HumanRandomized controlled trialSafety outcome

    In uncontrolled T2DM, gastrointestinal adverse events were more frequent with exenatide plus insulin glargine than placebo plus insulin glargine.

    In plain wordsIn diabetes, stomach and bowel side effects were more frequent when exenatide was added to insulin than when placebo was added.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseGastrointestinal adverse events
    Study

    n = 464

    Comparator
    Placebo plus insulin glargine
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    2 mg once weekly · 28 weeksAs given in this study (human).

    Measurements

    GI adverse events
    15.1%
    exenatide plus IG
    GI adverse events
    10.8%
    placebo plus IG

    Source sentences

    Summary
    Gastrointestinal and injection-site adverse events were more frequent with exenatide QW + IG (15.1% and 7.8%, respectively) than with placebo + IG (10.8% and 3.0%, respectively)
    1 context sentence
    Summary · context
    To compare the efficacy and safety of adding the glucagon-like peptide-1 receptor agonist exenatide once weekly (QW) 2 mg or placebo among patients with type 2 diabetes who were inadequately controlled despite titrated insulin glargine (IG) ± metformin.
  7. 07HumanRandomized controlled trialSafety outcome

    In uncontrolled T2DM, injection-site adverse events were more frequent with exenatide plus insulin glargine than placebo plus insulin glargine.

    In plain wordsIn diabetes, injection-site side effects were more frequent when exenatide was added to insulin than when placebo was added.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseInjection-site adverse events
    Study

    n = 464

    Comparator
    Placebo plus insulin glargine
    Outcome group
    Adverse events · Skin and wound
    Studied dose
    2 mg once weekly · 28 weeksAs given in this study (human).

    Measurements

    Injection-site adverse events
    7.8%
    exenatide QW plus IG
    Injection-site adverse events
    3%
    placebo plus IG

    Source sentences

    Summary
    Gastrointestinal and injection-site adverse events were more frequent with exenatide QW + IG (15.1% and 7.8%, respectively) than with placebo + IG (10.8% and 3.0%, respectively)
    1 context sentence
    Summary · context
    To compare the efficacy and safety of adding the glucagon-like peptide-1 receptor agonist exenatide once weekly (QW) 2 mg or placebo among patients with type 2 diabetes who were inadequately controlled despite titrated insulin glargine (IG) ± metformin.
  8. 08HumanRandomized controlled trialSafety outcome

    In uncontrolled T2DM, hypoglycaemia incidence was similar with exenatide plus insulin glargine and placebo plus insulin glargine.

    In plain wordsIn diabetes, low blood sugar occurred at similar rates when exenatide or placebo was added to insulin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeHypoglycaemia
    Study

    n = 464

    Comparator
    Placebo plus insulin glargine
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    2 mg once weekly · 28 weeksAs given in this study (human).

    Measurements

    Hypoglycaemia incidence
    29.7%
    exenatide QW plus IG
    Hypoglycaemia incidence
    29%
    placebo plus IG

    Source sentences

    Summary
    hypoglycaemia incidence was similar between the exenatide QW + IG (29.7%) and placebo + IG (29.0%) groups, with no major hypoglycaemic events.
    1 context sentence
    Summary · context
    To compare the efficacy and safety of adding the glucagon-like peptide-1 receptor agonist exenatide once weekly (QW) 2 mg or placebo among patients with type 2 diabetes who were inadequately controlled despite titrated insulin glargine (IG) ± metformin.
  9. 09HumanRandomized controlled trialSafety outcome

    In uncontrolled T2DM, no major hypoglycaemic events occurred with exenatide plus insulin glargine or placebo plus insulin glargine.

    In plain wordsIn diabetes, no major low blood sugar events occurred with either exenatide or placebo added to insulin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeMajor hypoglycaemia
    Study

    n = 464

    Comparator
    Placebo plus insulin glargine
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    2 mg once weekly · 28 weeksAs given in this study (human).

    Source sentences

    Summary
    hypoglycaemia incidence was similar between the exenatide QW + IG (29.7%) and placebo + IG (29.0%) groups, with no major hypoglycaemic events.
    1 context sentence
    Summary · context
    To compare the efficacy and safety of adding the glucagon-like peptide-1 receptor agonist exenatide once weekly (QW) 2 mg or placebo among patients with type 2 diabetes who were inadequately controlled despite titrated insulin glargine (IG) ± metformin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02229383

Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

AstraZenecan = 4646 Sept 2014 to 29 Aug 2016

Diabetes Mellitus

Trial pageClinicalTrials.govUpdated 8 Jan 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.